Drug Type Antibody drug conjugate (ADC) |
Synonyms MW C1 |
Target |
Action inhibitors |
Mechanism CLDN1 inhibitors(Claudin 1 inhibitors), Tubulin inhibitors |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC39H67N5O7 |
InChIKeyDASWEROEPLKSEI-UIJRFTGLSA-N |
CAS Registry474645-27-7 |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hepatocellular Carcinoma | Preclinical | China | 28 Apr 2025 | |
| Squamous Cell Carcinoma of Head and Neck | Preclinical | China | 28 Apr 2025 | |
| squamous cell lung carcinoma | Preclinical | China | 28 Apr 2025 | |
| Uterine Cervical Cancer | Preclinical | China | 28 Apr 2025 |






